Phenotypes associated with this allele

• Allele Symbol: Gpr68^tm1Aha
• Allele Name: targeted mutation 1, Akihiro Harada
• Allele ID: MGI:3837434
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Gpr68^tm1Aha/Gpr68^tm1Aha	B6.129-Gpr68^tm1Aha	MGI:3837444

Genotype
MGI:3837444

hm1

• Allelic Composition: Gpr68^tm1Aha/Gpr68^tm1Aha
• Genetic Background: B6.129-Gpr68^tm1Aha

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:189192 )

N • mice exhibit normal glucose tolerance

decreased insulin secretion ( J:189192 )

• after glucose administration in acidified isolated islets

• after glucose administration and treatment with carbachol but not vasopressin (AVP) or exendin-4 (Ex-4)

• after glucose administration and treatment with KCl or tolbutamide (TLB) but not PMA, forskolin or dimethyamiloride (DMA)

• after glucose stimulation and treatment with YM-254890 that is more severe in acidified islets

• however, islets stimulated with glucose or KCL exhibit normal insulin secretion when also treated with YM-254890 or 2-APB

decreased circulating glucose level ( J:189192 )

• small decrease after insulin administration

decreased circulating glucagon level ( J:189192 )

• prior to glucose administration

decreased circulating insulin level ( J:189192 )

• in fed mice and after glucose administration due to increased insulin clearance rate

increased insulin sensitivity ( J:189192 )

immune system

immune system phenotype ( J:146233 )

N • an acidic extracellular environment inhibits LPS-induced TNF secretion by macrophages in a manner similar to wild-type controls

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:189192 )

N • mice exhibit normal pancreatic islet morphology and physiology

N • mice exhibit normal glucose tolerance

decreased insulin secretion ( J:189192 )

• after glucose administration in acidified isolated islets

• after glucose administration and treatment with carbachol but not vasopressin (AVP) or exendin-4 (Ex-4)

• after glucose administration and treatment with KCl or tolbutamide (TLB) but not PMA, forskolin or dimethyamiloride (DMA)

• after glucose stimulation and treatment with YM-254890 that is more severe in acidified islets

• however, islets stimulated with glucose or KCL exhibit normal insulin secretion when also treated with YM-254890 or 2-APB